{
  "id": "S17",
  "slug": "biomedical-breakthrough-wave",
  "title": "Biomedical breakthrough wave",
  "version": "0.3.0",
  "status": "active",
  "orientation": "upside",
  "family": "E",
  "short_title": "Biomedical breakthroughs",
  "thematics": [
    "demographics-human-capital",
    "resilience-crisis-preparedness",
    "ai-cyber-digital"
  ],
  "likelihood_type": "systemic",
  "likelihood_note": null,
  "scores": {
    "likelihood_2y": {
      "band": 3,
      "rationale": "Three of the pieces are in rollout: generic semaglutide launched in India and Canada in 2026, twice-yearly lenacapavir reached more than 55,000 people in South Africa within months, and two malaria vaccines are in routine use. No AI-designed drug has yet been approved."
    },
    "likelihood_10y": {
      "band": 4,
      "rationale": "Pipelines in obesity, HIV, malaria and cancer vaccines mature within the decade."
    },
    "impact_systemic": {
      "level": 3,
      "rationale": "Level 3 as a gain: a healthier workforce and a lower disease burden, offset by pension and care costs."
    },
    "impact_national": {
      "level": 4,
      "rationale": "Level 4: high-burden nations gain years of healthy life; ageing nations face a pension and fiscal reset."
    },
    "confidence": {
      "level": "low",
      "reason": "Uptake, price and durability of effect are all uncertain."
    },
    "priority": 12,
    "tier": "II",
    "source": "ginc-desk-v0.3"
  },
  "scorecard": {
    "onset": "gradual (years)",
    "duration": "5 years",
    "warning": "months",
    "scope": "global",
    "origin": "accidental (technological)",
    "external_support": "partial",
    "policy_response": "current plans",
    "recovery_horizon": "structural"
  },
  "summary": "Several medical advances reach scale in the same five years: cheap generic obesity and diabetes drugs, long-acting HIV prevention, effective malaria vaccines, personalised cancer vaccines and the first medicines designed by AI. Together they cut the burden of the main killers by a fifth in countries that deploy them and add years of healthy life. Health systems shift from treatment to prevention. The gains depend on price, manufacturing and delivery, so they arrive first where systems already work. Longer lives strain pensions and care, and industries built on chronic disease shrink.",
  "distribution": {
    "gains": [
      "High-burden nations for HIV and malaria",
      "People with obesity, diabetes and cardiovascular disease",
      "Generic manufacturers",
      "Employers, through a healthier workforce"
    ],
    "loses": [
      "Pension funds and annuity providers",
      "Providers of chronic care such as dialysis",
      "Food and drink makers reliant on high consumption",
      "Nations that cannot fund delivery"
    ]
  },
  "narrative": {
    "dateline": "September 2031",
    "text": "The health ministry's annual report has a chart nobody has seen before: admissions for heart attack and stroke down for the third year, by a fifth in all. The obesity drug that cost a month's wages in 2024 is a generic tablet bought with the groceries. The HIV clinic in the township gives two injections a year and has recorded no new infection among its regular patients since it opened. In the villages to the north, the children's ward that filled every rainy season has empty beds; the malaria vaccine is given with the measles one. A cancer vaccine is made to order for each patient in six weeks, and the first drug designed end to end by a model has been on pharmacy shelves for a year. The actuaries noticed before the politicians. Life expectancy at 65 is up two years in five, the pension fund's deficit has doubled and the retirement age is back in parliament. A dialysis chain files for protection. Sugar and snack makers issue profit warnings. The harder story is next door, where the same medicines are licensed but the cold chain, the nurses and the budget are not there. Its government is asked why its citizens die of what the neighbours no longer catch."
  },
  "anchors": [
    {
      "shock_id": "combination-antiretroviral-therapy-1996",
      "date": "1996 onward",
      "event": "Combination antiretroviral therapy",
      "what_happened": "Turned HIV from a fatal to a chronic condition; access in Africa lagged by about a decade",
      "calibrates": "speed of benefit; the access gap"
    },
    {
      "shock_id": "covid-19-mrna-vaccines-2020",
      "date": "2020",
      "event": "COVID-19 mRNA vaccines",
      "what_happened": "Vaccines were authorised within about 11 months of the pathogen being sequenced",
      "calibrates": "speed of development at scale"
    },
    {
      "shock_id": "glp-1-medicines-2021",
      "date": "2021–2026",
      "event": "GLP-1 medicines",
      "what_happened": "Demand outran supply for years; generic semaglutide launched in India in March 2026 and was approved in Canada",
      "calibrates": "price as the gate to scale"
    },
    {
      "shock_id": "lenacapavir-for-hiv-prevention-2024",
      "date": "2024–2026",
      "event": "Lenacapavir for HIV prevention",
      "what_happened": "A twice-yearly injection; more than 55,000 people had started it in South Africa's public system by September 2026",
      "calibrates": "delivery in a high-burden setting"
    },
    {
      "shock_id": "malaria-vaccines-rts-s-and-r21-2021",
      "date": "2021–2024",
      "event": "Malaria vaccines RTS,S and R21",
      "what_happened": "WHO recommended RTS,S in 2021 and R21 in 2023; routine childhood use began in African countries in 2024",
      "calibrates": "low-cost prevention at scale"
    },
    {
      "shock_id": "ai-designed-drug-candidates-2026",
      "date": "July 2026",
      "event": "AI-designed drug candidates",
      "what_happened": "No AI-designed drug had full approval; the most advanced candidate entered a Phase III trial",
      "calibrates": "counter-anchor on speed"
    },
    {
      "shock_id": "smallpox-eradication-1980",
      "date": "1980",
      "event": "Smallpox eradication",
      "what_happened": "Declared eradicated after a global vaccination campaign",
      "calibrates": "Standard Extreme precedent"
    }
  ],
  "parameters": {
    "common": {
      "severity": {
        "major": "major",
        "severe": "severe",
        "extreme": "extreme"
      },
      "duration": {
        "major": null,
        "severe": "5 years",
        "extreme": null
      },
      "onset": {
        "major": null,
        "severe": "gradual (years)",
        "extreme": null
      },
      "warning": {
        "major": null,
        "severe": "months",
        "extreme": null
      },
      "scope": {
        "major": null,
        "severe": "global",
        "extreme": null
      },
      "origin": {
        "major": null,
        "severe": "accidental (technological)",
        "extreme": null
      },
      "external_support": {
        "major": null,
        "severe": "partial",
        "extreme": null
      },
      "concurrency": {
        "major": null,
        "severe": "standalone",
        "extreme": null
      },
      "policy_response": {
        "major": null,
        "severe": "current plans",
        "extreme": null
      },
      "recovery_horizon": {
        "major": null,
        "severe": "structural",
        "extreme": null
      }
    },
    "specific": [
      {
        "name": "Fall in burden of the leading causes of death where deployed",
        "default": "20 per cent",
        "range": "10–40",
        "unit": "per cent",
        "note": null
      },
      {
        "name": "Gain in healthy life expectancy",
        "default": "2 years",
        "range": "1–5",
        "unit": "years",
        "note": null
      },
      {
        "name": "Price relative to launch price",
        "default": "one tenth",
        "range": "one half to one hundredth",
        "unit": null,
        "note": null
      },
      {
        "name": "Lag between high-income and low-income access",
        "default": "5 years",
        "range": "1–15",
        "unit": "years",
        "note": null
      },
      {
        "name": "Technologies in the wave",
        "default": "5",
        "range": "3–8",
        "unit": null,
        "note": null
      },
      {
        "name": "Readiness of delivery systems",
        "default": "uneven",
        "range": "options: ready / absent",
        "unit": null,
        "note": null
      }
    ]
  },
  "transmission": [
    "Prices fall as generics and new manufacturers enter.",
    "Uptake scales through primary care and public programmes.",
    "Deaths and hospital admissions from the main chronic and infectious diseases fall.",
    "Workforce participation and productivity rise.",
    "Longevity raises pension and long-term care liabilities.",
    "Industries built on chronic disease contract; health budgets shift to prevention.",
    "Access gaps between and within nations become a political issue."
  ],
  "loading": [
    {
      "dimension": "Hard",
      "domain": "defence-security",
      "load": "Low",
      "channel": "fitter recruits; biosecurity of new platforms"
    },
    {
      "dimension": "Hard",
      "domain": "strategic-infrastructure",
      "load": "Medium",
      "channel": "cold chain, primary care and manufacturing sites"
    },
    {
      "dimension": "Hard",
      "domain": "critical-technology",
      "load": "High",
      "channel": "drug discovery, biomanufacturing and regulatory science"
    },
    {
      "dimension": "Soft",
      "domain": "government-effectiveness",
      "load": "High",
      "channel": "procurement, pricing, regulation and delivery at scale"
    },
    {
      "dimension": "Soft",
      "domain": "human-capital",
      "load": "High",
      "channel": "healthy life years, workforce participation, child survival"
    },
    {
      "dimension": "Soft",
      "domain": "influence-cohesion",
      "load": "Medium",
      "channel": "access inequality; health diplomacy"
    },
    {
      "dimension": "Economic",
      "domain": "macro-financial",
      "load": "High",
      "channel": "pension liabilities, health budgets, labour supply"
    },
    {
      "dimension": "Economic",
      "domain": "industry-trade-supply",
      "load": "Medium",
      "channel": "pharmaceutical trade; decline of chronic-care industries"
    },
    {
      "dimension": "Economic",
      "domain": "energy-resources",
      "load": "Low",
      "channel": "food demand shifts"
    }
  ],
  "stakeholders": {
    "government": {
      "exposure": "Health budgets, pension systems and the capacity to deliver at scale",
      "actions": [
        "Negotiate price and local manufacture early",
        "Shift budgets from hospital care to primary prevention",
        "Re-test pension systems on two more years of life"
      ],
      "watch": [
        "Generic entry dates",
        "Uptake by income group",
        "Hospital admissions for cardiovascular disease"
      ],
      "relevance": 3
    },
    "technology": {
      "exposure": "AI-led discovery and biomanufacturing platforms",
      "actions": [
        "Build regulatory-grade evidence, not only candidates",
        "Invest in manufacturing where demand is"
      ],
      "watch": [
        "First approvals of AI-designed medicines",
        "Trial success rates"
      ],
      "relevance": 4
    },
    "investors": {
      "exposure": "Pharmaceutical winners; insurers and pension funds exposed to longevity; chronic-care providers in decline",
      "actions": [
        "Test annuity and pension books on faster longevity gains",
        "Review holdings in food, dialysis and chronic-care services"
      ],
      "watch": [
        "Mortality improvement tables",
        "Patent expiries"
      ],
      "relevance": 4
    },
    "public": {
      "exposure": "Access and affordability; longer working lives",
      "actions": [],
      "watch": [
        "Coverage decisions",
        "Retirement age proposals"
      ],
      "relevance": 4
    }
  },
  "regions": [
    {
      "region": "north-america",
      "exposure": "High",
      "rationale": "High obesity and drug prices; large gains once prices fall"
    },
    {
      "region": "europe",
      "exposure": "High",
      "rationale": "Ageing populations gain health and face pension strain"
    },
    {
      "region": "china",
      "exposure": "High",
      "rationale": "Rapid ageing and large domestic manufacturing"
    },
    {
      "region": "indo-pacific",
      "exposure": "High",
      "rationale": "Japan and Korea face the sharpest longevity pressure"
    },
    {
      "region": "south-asia",
      "exposure": "High",
      "rationale": "Generic manufacturing base; large diabetes burden"
    },
    {
      "region": "gulf-middle-east",
      "exposure": "Medium",
      "rationale": "High diabetes prevalence; capacity to pay"
    },
    {
      "region": "africa",
      "exposure": "High",
      "rationale": "Largest gains from HIV and malaria prevention; delivery is the constraint"
    },
    {
      "region": "latin-america",
      "exposure": "Medium",
      "rationale": "Rising chronic disease; uneven systems"
    },
    {
      "region": "russia-eurasia",
      "exposure": "Medium",
      "rationale": "High cardiovascular mortality; access constrained"
    }
  ],
  "indicators": [
    {
      "name": "Price and generic availability of GLP-1 medicines by country",
      "source": null,
      "threshold": null,
      "cadence": null
    },
    {
      "name": "People on long-acting HIV prevention",
      "source": "UNAIDS, national programmes",
      "threshold": null,
      "cadence": null
    },
    {
      "name": "Malaria vaccine coverage and child mortality",
      "source": "WHO, Gavi",
      "threshold": null,
      "cadence": null
    },
    {
      "name": "Approvals of AI-designed medicines",
      "source": "FDA, EMA",
      "threshold": null,
      "cadence": null
    },
    {
      "name": "Cardiovascular admissions and mortality rates",
      "source": null,
      "threshold": null,
      "cadence": null
    },
    {
      "name": "Life expectancy at 65 and pension funding ratios",
      "source": null,
      "threshold": null,
      "cadence": null
    },
    {
      "name": "Late-stage cancer vaccine trial results",
      "source": null,
      "threshold": null,
      "cadence": null
    }
  ],
  "compounds": {
    "triggers": [
      {
        "id": "S04",
        "note": "pension liabilities in ageing sovereigns"
      }
    ],
    "triggered_by": [
      {
        "id": "S15",
        "note": "research acceleration"
      }
    ],
    "amplified_by": [],
    "triggered_by_other": [],
    "amplifying_trends": [
      "demographic ageing",
      "falling cost of sequencing and biomanufacturing",
      "rising chronic disease burden",
      "aid retrenchment"
    ]
  },
  "open_questions": [
    "Whether benefits that arrive over five years are a shock or a trend.",
    "How to score nations where the medicines are licensed but cannot be delivered.",
    "Whether longer lives count as a load on capability or a gain to it."
  ],
  "commentary": null,
  "overview": {
    "source": "ginc-desk-v0.3",
    "lenses": {
      "political": "The **retirement age is back in parliament**. Next door, a government is asked why its citizens die of what the neighbours no longer catch.",
      "economic": "Life expectancy at 65 is up two years in five and the **pension deficit has doubled**. A dialysis chain files for protection.",
      "social": "Heart attack and stroke admissions fall by **a fifth**. The children's ward that filled every rainy season has empty beds.",
      "technological": "A cancer vaccine is made to order in six weeks; the first drug **designed end to end by a model** is on the shelves.",
      "legal": "The medicines are **licensed everywhere**; price, patents and generic entry decide who gets them.",
      "environmental": "Food demand shifts as appetite-suppressing drugs scale; **snack and sugar makers** issue profit warnings."
    },
    "regions": {
      "north-america": "High obesity and high prices: **large gains once prices fall**.",
      "europe": "Ageing populations gain years of health and face **pension strain**.",
      "china": "**Rapid ageing** meets a large domestic manufacturing base.",
      "indo-pacific": "Japan and Korea face the **sharpest longevity pressure** on pensions and care.",
      "south-asia": "The **generic manufacturing base** supplies the world, and a large diabetes burden at home.",
      "gulf-middle-east": "High diabetes prevalence and the **capacity to pay**.",
      "africa": "The largest gains, from HIV and malaria prevention. **Delivery is the constraint**: cold chain, nurses and budget.",
      "latin-america": "Rising chronic disease and **uneven health systems**.",
      "russia-eurasia": "High cardiovascular mortality; **access is constrained**."
    }
  },
  "history": [
    {
      "edition": 2027,
      "rank": null,
      "L2y": 3,
      "L10y": 4,
      "impact_systemic": 3,
      "impact_national": 4,
      "confidence": "low"
    }
  ],
  "changelog": [
    {
      "version": "0.3.0",
      "date": "2026-10-03",
      "change": "Entered the Library at v0.3 as an upside scenario, with GINC desk scores."
    }
  ],
  "citation": "GINC (2027). Scenario S17 Biomedical breakthrough wave, Scenario Library v0.3. scenarios.ginc.org/library/biomedical-breakthrough-wave"
}